These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 32327473)

  • 21. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies.
    Zarlashat Y; Mushtaq H; Pham L; Abbas W; Sato K
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
    Zhu Y; Qin LX
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab for the treatment of hepatocellular carcinoma.
    Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
    Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
    da Fonseca LG; Reig M; Bruix J
    Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
    Yao X; Wang L; Gao J
    Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
    Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
    J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019.
    Tovoli F; Casadei-Gardini A; Benevento F; Piscaglia F
    Dig Liver Dis; 2019 Aug; 51(8):1067-1073. PubMed ID: 31208929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New systemic agents for hepatocellular carcinoma: an update 2020.
    von Felden J
    Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
    Boland P; Wu J
    Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy.
    De Somer T; Vanderstraeten E; Bouderez V; Monsaert E; Van Steenkiste C
    Acta Clin Belg; 2022 Feb; 77(1):108-112. PubMed ID: 32529925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Therapy in Metastatic Hepatocellular Carcinoma.
    Elms D; Badami A; Dhanarajan A
    Curr Gastroenterol Rep; 2022 May; 24(5):65-71. PubMed ID: 35416635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of inoperable hepatocellular carcinoma with immunotherapy.
    Tighe SP; Iqbal U; Fernandes CT; Ahmed A
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31352386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment.
    Kumar AR; Devan AR; Nair B; Nath LR
    Curr Drug Targets; 2021; 22(11):1288-1316. PubMed ID: 33538672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
    Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.